Hepatitis B and C in the liver transplant recipient

Seminars in Liver Disease

Volumn 20, Issue 4, 2000, Pages 465-480

  Rosen, H R ^a   Martin, P ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Hepatitis B; Hepatitis C; Viral recurrence

Indexed keywords

HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE;

ARTICLE; CHRONIC HEPATITIS; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECIPIENT; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; TREATMENT INDICATION; VIRUS LOAD;

GRAFT ENHANCEMENT, IMMUNOLOGIC; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 0034520998     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-13156     Document Type: Article

References (123)

1. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
2. Hepatitis B virus and liver transplantation
3. Liver transplantation in European patients with the hepatitis B surface antigen
4. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post transplantation
5. Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vitro
6. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
7. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
8. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
9. Improved survival of hepatitis B patients undergoing liver transplantation: Effects in-dependent of therapeutic interventions
10. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
11. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
12. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis
13. Predictors of patient and graft survival following liver transplantation for hepatitis C
14. Liver transplantation in European patients with the hepatitis B surface antigen
15. Liver transplantation for chronic hepatitis B in Asians
16. Liver transplantation in Asian patients with chronic hepatitis B
17. Does Asian race affect hepatitis B virus recurrence or survival following liver transplantation for hepatitis B cirrhosis?
18. Retransplantation for hepatitis B - A multicenter experience
19. Retransplantation of patients with severe posttransplant hepatitis B in the first allograft
20. Retransplantation of the liver for recurrent hepatitis B virus infection: The Paul Brousse experience
21. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis
22. Long-term outcome of liver transplant recipients in the US
23. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis
24. Patterns of hepatitis delta virus reinfection and disease in liver transplantation
25. Hepatitis B and C coinfections and persistent hepatitis B infections: Clinical outcome and liver pathology after transplantation
26. Dual effects of hepatitis B (HBV) infection and hepatitis B immunoglobulin in reducing the incidence of acute rejection post transplantation
27. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis
28. Hepatitis D Viremia following orthotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope
29. The interaction between hepatitis B and hepatitis C virus in acute and chronic liver disease
30. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation
31. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen
32. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants
33. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
34. Infectivity of hepatic allografts with antibodies to hepatitis B virus
35. Severe clinical course of de novo hepatitis B infection after liver transplantation
36. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
37. Clinical course and survival after liver transplantation for hepatitis B virus infection complicated by hepatocellular carcinoma
38. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence
39. Antiviral therapy before and after liver transplantation
40. Interferon alpha for recurrent hepatitis B infection after liver transplantation
41. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
42. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
43. Prevention of recurrent hepatitis B infection following liver transplantation: Experience in 112 North American patients
44. Outcome of lamivudine, resistant hepatitis B virus infection in the liver transplant recipient
45. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
46. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
47. Intramuscular hepatitis B immune globulin continued with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation
48. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation
49. Antiviral chemotherapy for the treatment of hepatitis B virus infections
50. The epidemiology of acute and chronic hepatitis C
51. Hepatitis C virus infection following liver transplantation
52. Hepatitis C virus: Molecular aspects and implications for future therapy
53. Hepatitis C virus-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
54. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections
55. Clinical outcomes after transfusion-associated hepatitis C
56. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response
57. Natural history of liver fibrosis progression in patients with chronic hepatitis C
58. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
59. A longitudinal analysis of hepatitis C virus replication following liver transplantation
60. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions
61. Long-term outcome of hepatitis C virus infection after liver transplantation
62. Graft loss following liver transplantation in patients with chronic hepatitis C
63. Long-term outcome of hepatitis C infection after liver transplantation
64. Timing and severity of hepatitis C recurrence following liver transplantation as predictors of longterm allograft injury
65. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes
66. Clinical and histologic patterns in early graft failure due to recurrent hepatitis C infection after liver transplantation
67. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
68. Quantitation of hepatitis C virus RNA in liver transplant recipients
69. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features
70. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation
71. The influence of hepatitis C virus genotype on the outcome of liver transplantation
72. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia
73. Histological and clinical outcome after liver transplantation for hepatitis C
74. Do viral genotypes and HLA matching influence the outcome of recurrent hepatitis C virus infection after liver transplantation?
75. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection
76. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients
77. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: Correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns
78. Tacrolimus versus cyclosporine immunosuppression in liver transplantation for hepatitis C
79. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation
80. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation
81. A prospective controlled trial of tacrolimus vs. cyclosporine in orthotopic liver transplant recipients with hepatitis C virus: Lack of effect on recurrent hepatitis
82. Liver transplantation
83. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of NIDDK Liver Transplantation Database
84. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation
85. Use of OKT3 (monoclonal antibody) associated with early and severe hepatitis C recurrence following liver transplantation
86. OKT3 and hepatitis C: Defining the risks
87. Cytomegalovirus viremia: Risk factor for allograft cirrhosis following liver transplantation for hepatitis C
88. Increased mortality following CMV infection in patients transplanted for HCV: Results of the NIDDK liver transplantation database
89. Association of multi-specific CD4+ response to hepatitis C and severity of recurrence after liver transplantation
90. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation
91. Donor polymorphism of tumor necrosis factor gene associated with variable severity of hepatitis C recurrence following liver transplantation
92. Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis
93. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation
94. Hepatitis C virus recurrence after liver transplantation: Relationship to anti-HCV core IgM, genotype, and level of viremia
95. The humoral immune response to hepatitis C following liver transplantation: Assessment of a new immunoblot assay
96. Late hepatic artery thrombosis: A potential complication of viral hepatitis
97. Hepatitis C associated glomerulonephritis
98. Impact of donor hepatitis C infection on recipient outcome following liver transplantation in the hepatitis C positive recipient: An analysis of the UNOS data
99. Outcome of liver transplantation in hepatitis C virus-infected grafts
100. Hepatitis C infection in patients undergoing liver retransplantation
101. Outcome of liver retransplantation for recurrent hepatitis C infection
102. Poor prognosis of patients retransplanted for recurrent liver disease due to hepatitis C virus
103. Recurrent hepatitis C after liver transplantation
104. Retransplantation for hepatitis C: Implications of different policies
105. Treatment strategies for recurrent hepatitis C after liver transplantation
106. Treatment of recurrent hepatitis C virus infection after liver transplantation
107. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation
108. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection
109. A randomized study comparing ribavirin and interferon alpha monotherapy for hepatitis C recurrence after liver transplantation
110. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients
111. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation
112. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation
113. Combination therapy of interferon alpha 2-b and ribavirin for recurrent hepatitis C after liver transplantation
114. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
115. Recurrent HCV infection following OLTX
116. Interferon-a for prophylaxis of recurrent hepatitis C in liver transplant recipients
117. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination
118. Recurrent hepatitis C after liver transplantation: Clinical and therapeutical issues
119. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
120. Late-onset renal failure after liver transplantation: Role of posttransplant alcohol use
121. Quality of life in long-term survivors after liver transplantation: Impact of recurrent viral hepatitis C virus hepatitis